Nukkleus Inc. Reports Board and Executive Changes

Ticker: DFNSW · Form: 8-K · Filed: Mar 8, 2024 · CIK: 1787518

Sentiment: neutral

Topics: management-change, board-of-directors, executive-compensation

Related Tickers: NUKK

TL;DR

Nukkleus Inc. shook up its board and exec team on Feb 9th. Watch for strategy shifts.

AI Summary

Nukkleus Inc. filed an 8-K on February 9, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel. Specific names and dollar amounts related to these changes are not detailed in the provided excerpt.

Why It Matters

Changes in a company's board and executive team can signal shifts in strategy, operational focus, or governance, potentially impacting future performance and investor confidence.

Risk Assessment

Risk Level: medium — Changes in directorship and executive compensation can indicate internal shifts that may affect company direction and stability.

Key Players & Entities

FAQ

What specific roles did the departing officers and directors hold at Nukkleus Inc.?

The provided excerpt does not specify the exact roles of the departing officers and directors.

Who were the newly elected directors of Nukkleus Inc.?

The excerpt mentions the election of new directors but does not name them.

What were the key changes in compensatory arrangements for the officers?

The filing indicates updates to compensatory arrangements, but the specific details are not included in this excerpt.

On what date were these changes to the board and executive team effective?

The earliest event reported is dated February 9, 2024.

What is the business address of Nukkleus Inc.?

The business address is 525 Washington Blvd, Jersey City, NJ 07310.

Filing Stats: 496 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-03-08 17:00:36

Key Financial Figures

Filing Documents

02. Departure of Directors or Certain

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 9, 2024, Tony Porcheron resigned as Chief Financial Officer of Nukkleus Inc. (the "Company") without cause, effective immediately. On February 12, 2024, Emil Assentato was appointed, effective February 12, 2024, to serve as interim Chief Financial Officer of the Company. Mr. Porcheron's resignation is not a result of any disagreement regarding the Company's financial reporting or accounting policies, procedures, estimates or judgments. Mr. Assentato will also continue to serve in his role as Chief Executive Officer of the Company, and the Company will be conducting a search for a permanent chief financial officer. There are no arrangements or understandings between Mr. Assentato and any other persons pursuant to which Mr. Assentato was appointed as interim Chief Financial Officer. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Nukkleus Inc. (Registrant) Dated: March 8, 2024 By: /s/ Emil Assentato Name: Emil Assentato Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing